Clinical trials: Lymphoid Hematological Malignancies
Hematologic Diseases, Chronic Myeloid Leukemia
Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant
PURPOSE: To investigate the effect of the disease and HSCT on muscle dysfunction and to investigate the prognostic role of muscle dysfunction at critical decision points in patients with hematological diseases referred to…
- Conditions
- Hematologic Diseases, Chronic Myeloid Leukemia, Acute Myeloid Leukemia, Acute Lymphoid Leukemia
- Trial name
- NCT04167683
- Testing
- No intervention
- Where
- Denmark
- Volunteers
- 144 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
CD5+ Relapsed/Refractory Hematopoietic Malignancies, Chronic Lymphocytic Leukemia (CLL)
Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies
Current treatments for relapsed/refractory hematopoietic malignancies such as B-cell lymphomas (BCLs) and peripheral T-cell lymphomas (PTCLs) are far from satisfactory.
- Conditions
- CD5+ Relapsed/Refractory Hematopoietic Malignancies, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), Diffuse Large B-cell Lymphoma (DLBCL)
- Trial name
- NCT04767308
- Testing
- CT125A cells, Cyclophosphamide, fludarabine
- Volunteers
- 18 people
- Sponsor
- Huazhong University of Science and Technology
Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
This phase I trial studies the side effects and the best dose of intensity modulated total marrow irradiation (IMTMI) when given together with fludarabine phosphate and melphalan in treating patients with cancers of the blood…
- Conditions
- Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Hematologic Malignancy
- Trial name
- NCT02333162
- Testing
- Fludarabine Phosphate, Melphalan, Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Chicago